Niraparib

Generic Name
Niraparib
Brand Names
Zejula
Drug Type
Small Molecule
Chemical Formula
C19H20N4O
CAS Number
1038915-60-4
Unique Ingredient Identifier
HMC2H89N35
Background

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...

Indication

Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy

Phase 2
Withdrawn
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Niraparib
First Posted Date
2022-06-09
Last Posted Date
2023-09-08
Lead Sponsor
Ospedale Policlinico San Martino
Registration Number
NCT05412706

Niraparib In Recurrent IDH 1/2 Gliomas

First Posted Date
2022-06-06
Last Posted Date
2024-03-29
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
16
Registration Number
NCT05406700
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

Phase 2
Not yet recruiting
Conditions
Epithelial Ovarian Cancer
Interventions
Drug: Niraparib
First Posted Date
2022-05-23
Last Posted Date
2022-05-23
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
35
Registration Number
NCT05385068

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

First Posted Date
2022-04-20
Last Posted Date
2024-01-16
Lead Sponsor
CanariaBio Inc.
Target Recruit Count
10
Registration Number
NCT05335993
Locations
🇺🇸

Duke Cancer Center, Durham, North Carolina, United States

🇺🇸

Stephenson Cancer Center- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

🇺🇸

University of Virginia Health System, Charlottesville, Virginia, United States

PARP Inhibition for Gliomas (PI-4G or π4g)

First Posted Date
2022-03-28
Last Posted Date
2024-11-06
Lead Sponsor
University of Oklahoma
Target Recruit Count
15
Registration Number
NCT05297864
Locations
🇺🇸

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

First Posted Date
2022-03-02
Last Posted Date
2023-12-13
Lead Sponsor
Dantari, Inc.
Target Recruit Count
30
Registration Number
NCT05261269
Locations
🇺🇸

UCLA - Parkside Cancer Center, Santa Monica, California, United States

🇺🇸

Magee Women's Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 6 locations

SMMART Adaptive Clinical Treatment (ACT) Trial

Early Phase 1
Withdrawn
Conditions
Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Prostate Carcinoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Breast Carcinoma
Stage IV Ovarian Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Interventions
Drug: Alectinib
Drug: Alpelisib
Drug: Anastrozole
Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Drug: Carboplatin
Drug: Cobimetinib
Drug: Entrectinib
Drug: Eribulin
Drug: Fulvestrant
Biological: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Drug: Irinotecan
Drug: Letrozole
Drug: Nab-paclitaxel
Drug: Niraparib
Drug: Olaparib
Drug: Paclitaxel
Drug: Palbociclib
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab
Biological: Trastuzumab Emtansine
Drug: Vemurafenib
Drug: Vinorelbine
Drug: Vismodegib
First Posted Date
2022-02-14
Last Posted Date
2024-01-23
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT05238831

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

First Posted Date
2022-02-09
Last Posted Date
2022-03-08
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
12
Registration Number
NCT05232006

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

First Posted Date
2022-01-20
Last Posted Date
2024-06-24
Lead Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Target Recruit Count
117
Registration Number
NCT05198804
Locations
🇺🇸

Rutgers New Jersey Medical School, Newark, New Jersey, United States

🇺🇸

Virginia Cancer Specialists, Fairfax, Virginia, United States

🇺🇸

Arizona Oncology Associates (Wilmot HOPE) - USOR, Tucson, Arizona, United States

and more 17 locations

Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

First Posted Date
2022-01-11
Last Posted Date
2024-10-16
Lead Sponsor
ARCAGY/ GINECO GROUP
Target Recruit Count
390
Registration Number
NCT05183984
Locations
🇫🇷

Clinique Victor Hugo, Le Mans, France

🇫🇷

CHU Montpellier - Hôpital Saint Eloi, Montpellier, France

🇫🇷

Hôpital Saint-Joseph, Paris, France

and more 84 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy